心脏毒性难题:区分免疫检查点抑制剂心肌炎与同时治疗中的甲心脏毒性
Vivian Hu1, Ishan Naidu1, Nausheen Singh1
1Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
在使用免疫检查点抑制剂 (ICI) 与化疗时,确定心脏毒性的原因是具有挑战性的. 及时诊断影响癌症治疗和患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗,但可能导致罕见的心脏毒性.
- 同时的化疗,如甲 (5FU),具有明显的心脏风险.
- 重叠的毒性使得结合癌症治疗中的诊断复杂化.
更多相关视频
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
相关概念视频
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy IV: Restrictive Cardiomyopathy
